Phase 1 Start

IBRX: Phase1_Start: Open-Label, Single-Arm, Phase 1b Clinical Trial of NAI Plus Pembrolizumab With Short Course of Enfortumab Vedotin in Treatment-Naïve Participants With Metastatic Urothelial Carcinoma

Name: Phase1_Start: Open-Label, Single-Arm, Phase 1b Clinical Trial of NAI Plus Pembrolizumab With Short Course of Enfortumab Vedotin in Treatment-Naïve Participants With Metastatic Urothelial Carcinoma
Start: 2026-12-01
End: 2026-12-01

December 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2026
Company: ImmunityBio, Inc. (IBRX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 1 Start

Phase1_Start: Open-Label, Single-Arm, Phase 1b Clinical Trial of NAI Plus Pembrolizumab With Short Course of Enfortumab Vedotin in Treatment-Naïve Participants With Metastatic Urothelial Carcinoma

December 1, 2026

IBRX overview →

Company: ImmunityBio, Inc. (IBRX)

Other upcoming events for IBRX

Phase 2 StartPhase2_Start: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbakicept (NAI) Plus Standard of Care (SOC) Compared to SOC Alone in Critically Ill Adults With Sepsis

Oct 15, 2026